Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.107060%-
Abdominal distension07.01.04.0010.019082%
Abdominal pain07.01.05.0020.154642%
Abdominal pain lower07.01.05.010---
Abdominal pain upper07.01.05.0030.123044%
Abdominal tenderness07.01.05.0040.004337%-
Abnormal faeces07.01.03.001---
Acidosis14.01.03.0020.001239%
Acidosis hyperchloraemic14.01.01.0070.003965%-
Acne23.02.01.001---
Acute hepatic failure09.01.03.0010.005576%-
Acute leukaemia01.10.02.001; 16.01.02.0010.006443%-
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.027880%-
Adenocarcinoma16.16.01.0040.001239%-
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Alanine aminotransferase increased13.03.04.005--
Albuminuria20.02.01.0010.002478%-
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.0030.006196%-
Alveolar proteinosis10.04.04.018; 22.01.02.0090.001239%-
Amaurosis fugax06.02.10.002; 17.08.04.002; 24.04.06.0060.001239%-
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.0010.064930%
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Aneurysm24.02.01.0010.001859%-
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anorectal disorder07.03.01.0010.001239%-
Anuria20.01.03.0020.003717%-
The 1th Page    1 2 3 4 5    Next   Last    Total 18 Pages